<DOC>
	<DOC>NCT01530256</DOC>
	<brief_summary>The purpose of this study is to determine the safe and tolerable, biologically active, and potentially effective doses(s) of ALD518 in subjects with acute GVHD, who have failed to respond to glucocorticosteroids, for further investigation in Part B.</brief_summary>
	<brief_title>Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)</brief_title>
	<detailed_description />
	<criteria>Glucocorticosteroid refractory acute GVHD Grade 24 Prior corticosteroid therapy at &gt; 1.0mg/kg methylprednisolone or equivalent for minimum of 3 and maximum of 14 days Karnofsky Performance Satus Scale â‰¥ 50% Adequate laboratory testing at screening Subjects having Stage 1 skin acute GVHD Subjects with Stage 3 or 4 liver GVHD Prior EBV associated malignancy Prior or current Hepatitis B or C Prior or active tuberculosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>allograph</keyword>
	<keyword>steroid refractory</keyword>
</DOC>